Literature DB >> 25160741

Phosphodiesterase isoenzymes in the human urethra: a molecular biology and functional study.

George T Kedia1, Matthias Oelke2, Joachim E Sonnenberg3, Michael Sohn4, Andreas Bannowsky5, Markus A Kuczyk2, Stefan Ückert6.   

Abstract

Experimental and clinical studies have suggested a role for phosphodiesterase (PDE) isoenzymes in the control of the human lower urinary tract. This study aimed to investigate the expression of PDE isoenzymes and the effects of PDE inhibitors (PDE-Is) in isolated human urethral smooth muscle (USM). The expression of messenger ribonucleic acid (mRNA) specifically encoding for PDE isoenzymes and isoforms (1A, 1B, 1C, 2A, 4A, 4B, 4C, 4D, 5A and 11A) was analyzed by means of reverse transcriptase polymerase chain reaction (RT-PCR). Using a tissue bath technique, the effects of vinpocetine (PDE1-I), erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride (EHNA-HCl=MEP1) (PDE2-I), rolipram (PDE4-I), sildenafil, vardenafil and tadalafil (PDE5-Is) (0.01-10µM) on the tension of USM induced by norepinephrine were investigated. The production of cyclic guanosine monophosphate (cyclic GMP) and cyclic adenosine monophosphate (cyclic AMP) was measured by means of radioimmunoassays. RT-PCR analysis revealed the expression of PDE1B, PDE1C, PDE4A, PDE4C, PDE4D, PDE5A and PDE11A. The tension induced by norepinephrine (NE) was reversed by the PDE inhibitors with the following rank order of efficacy: rolipram (mean: -39%)≥sildenafil (-35%)>vardenafil (-26%)>tadalafil (-20%)>vinpocetine (-16%)>MEP1 (-2%). The relaxing effects of the drugs were paralleled by an elevation in tissue levels of cyclic AMP and cyclic GMP. Selective inhibitors of PDE4 and PDE5 can antagonize the tension induced by alpha-adrenergic stimulation of USM. PDE inhibition might represent an interesting option to facilitate the relaxation of the human outflow region.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cyclic AMP; Cyclic GMP; Forskolin (PubChem CID: 47936); Human male urethra; MEP 1=EHNA-HCl (erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride) (PubChem CID: 11957547); Norepinephrine (PubChem CID: 439260); Phosphodiesterase enzymes; Rolipram (PubChem CID: 5092); Sildenafil citrate (PubChem CID: 62853); Sodium nitroprusside (PubChem CID: 11963622); Tadalafil (PubChem CID: 110635); Vardenafil (PubChem CID: 110634); Vinpocetine (PubChem CID: 443955)

Mesh:

Substances:

Year:  2014        PMID: 25160741     DOI: 10.1016/j.ejphar.2014.08.005

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Selective phosphodiesterase-2A inhibitor alleviates radicular inflammation and mechanical allodynia in non-compressive lumbar disc herniation rats.

Authors:  Jun-Nan Wang; Xue-Jun Zhao; Zhi-Hua Liu; Xu-Li Zhao; Tao Sun; Zhi-Jian Fu
Journal:  Eur Spine J       Date:  2017-03-10       Impact factor: 3.134

2.  Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra.

Authors:  Harrina E Rahardjo; Stefan Ückert; Andreas Bannowsky; Markus A Kuczyk; George T Kedia
Journal:  Res Rep Urol       Date:  2021-03-19

3.  Inhibition by tadalafil of contractility of isolated nonpregnant human myometrium.

Authors:  Sumalya Sen; Anitha Thomas; Saibal Das; Jayanta Kumar Dey; Abraham Peedicayil; Vinotha Thomas; Jacob Peedicayil
Journal:  J Pharmacol Pharmacother       Date:  2016 Oct-Dec

4.  Phosphodiesterase type 4 inhibition enhances nitric oxide- and hydrogen sulfide-mediated bladder neck inhibitory neurotransmission.

Authors:  Ángel Agis-Torres; Paz Recio; María Elvira López-Oliva; María Pilar Martínez; María Victoria Barahona; Sara Benedito; Salvador Bustamante; Miguel Ángel Jiménez-Cidre; Albino García-Sacristán; Dolores Prieto; Vítor S Fernandes; Medardo Hernández
Journal:  Sci Rep       Date:  2018-03-16       Impact factor: 4.379

5.  Efficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs.

Authors:  Xifeng Sun; Wei Guan; Haoran Liu; Kun Tang; Libin Yan; Yangjun Zhang; Jin Zeng; Zhiqiang Chen; Hua Xu; Zhangqun Ye
Journal:  BMC Urol       Date:  2018-05-03       Impact factor: 2.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.